logo

Cara Therapeutics Inc. (CARA)



Trade CARA now with
  Date
  Headline
12/3/2019 7:04:04 AM Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial Of Oral KORSUVA
10/14/2019 7:09:03 AM Cara Therapeutics Completes Interim Statistical Assessment Of Pivotal KALM-2 Phase 3 Trial Of KORSUVA Injection
8/21/2019 7:07:09 AM Enteris BioPharma, Cara Therapeutics Enter Licensing Deal For Peptelligence To Advance Development Of Oral KORSUVA
7/24/2019 9:00:30 PM Cara Therapeutics Prices Underwritten Public Offering Of 5.50 Mln Shares At $23.00/shr
7/22/2019 7:12:22 AM Cara Therapeutics Announces No Modifications In Trial Size For Phase 2 Trial Of Oral KORSUVA; Sees Topline Data In Q4
7/11/2019 8:44:00 AM Enteris Initiates Phase 2 Trial Of Peptelligence-Engineered Oral KORSUVA For Pruritus In Patients With Atopic Dermatitis
7/9/2019 7:06:07 AM Cara Therapeutics Begins Phase 2 Trial Of Oral KORSUVA For Pruritus In Patients With Atopic Dermatitis
6/26/2019 7:14:45 AM Cara Therapeutics Begins Phase 2 Trial Of Oral KORSUVA For Pruritus In Patients With Primary Biliary Cholangitis
5/29/2019 7:07:32 AM Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial Of KORSUVA Injection
1/7/2019 7:13:18 AM Cara Completes Enrollment Of KALM-1 Pivotal Phase 3 Trial Of KORSUVA Injection In Hemodialysis Patients With Pruritus
1/2/2019 7:12:41 AM Cara Therapeutics Says No Modifications In KALM-1 Phase 3 Trial Of KORSUVA
7/19/2018 8:12:40 AM Cara Therapeutics Doses First Patient In Phase 2 Trial Of Peptelligence-Engineered Oral KORSUVA
  
 
>